<DOC>
	<DOCNO>NCT02755844</DOCNO>
	<brief_summary>Endometrial cancer rank 11th term incidence ( 7275 / year ) mortality ( 2025 deaths/ year ) . The 5-year overall survival patient diagnosis locally advanced metastatic carcinoma 50 % 15 % respectively . Beyond first line treatment platinum-based chemotherapy , lack effective drug disease , explain poor prognosis patient . The prognosis metastatic endometrial cancer patient poor , drug show effective beyond first chemotherapy line . Endometrial carcinoma characterize frequent alteration PI3K-AKT-mTor ; IGF1R DNA repair pathway . Phosphatase tensin homologue ( PTEN ) -phosphoinositide 3-kinase ( PI3K ) -mammalian target rapamycin ( mTor ) DNA repair pathway interact , inhibition PI3K-AKT-mTor signal pathway may alter DNA damage repair . Metronomic cyclophosphamide regimen may increase anti-proliferative effect olaparib alkylating agent , exert anti-angiogenic effect , favorable toxicity profile . Metformin may increase anti-proliferative effect olaparib downregulates IGF1R PI3K-AKT-mTor pathway , additive toxicity .</brief_summary>
	<brief_title>Safety Efficacy Metronomic Cyclophosphamide , Metformin Olaparib Endometrial Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Woman older 18 year younger 81 year old Patients histologically and/or cytologically document endometrial carcinoma ( type I type II ) , recurrent platinumbased chemotherapy . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Archival tumor tissue available , tumor lesion biopsy feasible There limitation prior number therapy Patients measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Patients adequate bone marrow function Absolute granulocyte count ≥ 1.5 x 10 9 /L Platelet count ≥ 100 x 10 9 /L Haemoglobin ≥ 9 g/dL Patients adequate renal function : * Calculated creatinine clearance , accord Modification Diet Renal Disease ( MDRD ) formula &gt; = 60 ml/min Patients adequate hepatic function *Serum total bilirubin &lt; 1.25 x upper normal limit ( UNL ) aspartate aminotransferase ( AST ) /Alanine Amino transferase ( ALT ) ≤ 2.5 X UNL ( ≤ 5 X UNL patient liver metastasis ) Patients must life expectancy ≥ 16 week Female patient childbearing potential : evidence nonchildbearing status , practice medically acceptable method birth control study 12 month end treatment Patients give write informed consent participate study Patients affiliate social insurance regime Illness , incompatible metformin treatment , particular associate risk hypoperfusion hypoxia ( limited ) : acute chronic renal failure ( creatinine clearance &lt; 60 ml/min , accord MDRD formula ) ; lactic ketoacidosis ; septic shock ; congestive heart failure ; respiratory distress ; liver failure ; chronic alcoholism ; uncontrolled seizure ; age &gt; 80 year ; allergy/hypersensitivity metformin . Previous treatment cyclophosphamide ; allergy/hypersensitivity cyclophosphamide . Any previous treatment polyadenosine diphosphate ribose ( ADP ) ribose polymerase ( PARP ) inhibitor , include olaparib . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≥ 5 year . Patients receive systemic chemotherapy , radiotherapy ( except palliative reason ) , within 2 week last dose prior study treatment . The patient receive stable dose bisphosphonates bone metastasis , study long start least 4 week prior treatment study drug . Concomitant use know CYP3A4 inhibitor ketoconazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin boceprevir , telaprevir nelfinavir inducer phenobarbital , phenytoin , carbamazepine , rifampicin . Persistent toxicity ( &gt; =CTCAE grade 2 ) exception alopecia , cause previous cancer therapy . Treatment investigational agent . Bowel occlusive syndrome gastrointestinal disorder allow oral medication malabsorption . Female patient pregnant lactating , Active infection HIV , hepatitis B C , form hepatitis cirrhosis . Symptomatic uncontrolled brain metastasis . The patient receive stable dose corticosteroid study long start least 28 day prior treatment . Major surgery within 14 day start study treatment Patients must recover effect major surgery . Resting ECG correct QT interval ( QTc ) &gt; 470msec 2 time point within 24 hour period family history long QT syndrome . Concomitant treatment vitamin K antagonists Patients guardianship .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>endometrial carcinoma</keyword>
	<keyword>metronomic cyclophosphamide</keyword>
	<keyword>metformin</keyword>
	<keyword>olaparib</keyword>
	<keyword>dose-escalation study</keyword>
</DOC>